An open label randomized multicentre phase IIIb trial comparing parenteral substitution versus best supportive nutritional care in subjects with pancreatic adenocarcinoma receiving 5-FU plus oxaliplatin as 2nd or higher line chemotherapy regarding clinical benefit - PANUSCO

BMC Cancer

Volumn 9, Issue , 2009, Pages

  Märten, Angela ^a,b   Wente, Moritz N ^a,b   Ose, Jennifer ^a,b   Büchler, Markus W ^a   Rötzer, Ingeborg ^b   Decker Baumann, Christiane ^b   Karapanagiotou Schenkel, Irini ^b   Harig, Sabine ^a,b   Schmidt, Jan ^a   Jäger, Dirk ^b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; FOLINIC ACID; OXALIPLATIN; ANTINEOPLASTIC AGENT; PLATINUM COMPLEX;

ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; ENTERIC FEEDING; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NUTRITIONAL ASSESSMENT; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PARENTERAL NUTRITION; PHASE 3 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; TREATMENT RESPONSE; ADENOCARCINOMA; AGED; CACHEXIA; DIET THERAPY; METHODOLOGY; MIDDLE AGED; PANCREAS TUMOR;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CACHEXIA; FLUOROURACIL; HUMANS; MIDDLE AGED; NUTRITION THERAPY; ORGANOPLATINUM COMPOUNDS; PANCREATIC NEOPLASMS; PARENTERAL NUTRITION; YOUNG ADULT;

EID: 71549146257     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-9-412     Document Type: Article

References (14)

1. Jemal A, Siegel R, Ward E, Hao A, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009, 59:225-249. 10.3322/caac.20006, 19474385.
2. Cohen SJ, Pinover WH, Watson JC, Meropol NJ. Pancreatic cancer. Current Treat Options Oncol 2000, 1:375-386.
3. Ockenga J, Valentini L. Review article: anorexia and cachexia in gastrointestinal cancer. Aliment Pharmacol Ther 2005, 22:583-594. 10.1111/j.1365-2036.2005.02628.x, 16181298.
4. Uomo G, Gallucci F, Rabitti PG. Anorexia-cachexia syndrome in pancreatic cancer: recent development in research and management. JOP 2006, 7:157-162.
5. Bossola M, Pacelli F, Tortorelli A, Doglietto GB. Cancer cachexia: it's time for more clinical trials. Ann Surg Oncol 2007, 14:276-285. 10.1245/s10434-006-9179-5, 17094025.
6. Bauer JD, Capra S. Nutrition intervention improves outcomes in patients with cancer cachexia receiving chemotherapy--a pilot study. Support Care Cancer 2005, 13:270-274. 10.1007/s00520-004-0746-7, 15583950.
7. Shang E, Weiss C, Post S, Kaehler G. The influence of early supplementation of parenteral nutrition on quality of life and body composition in patients with advanced cancer. JPEN J Parenter Enteral Nutr 2006, 30:222-230. 10.1177/0148607106030003222, 16639069.
8. Peltz G. Nutrition support in cancer patients: a brief review and suggestion for standard indications criteria. Nutr J 2002, 1:1. 139958, 12537597, 10.1186/1475-2891-1-1.
9. Bozzetti F, Arends J, Lundholm K, Micklewright A, Zurcher G, Muscaritoli M. ESPEN guidelines on parenteral nutrition: non-surgical oncology. Clin Nutr 2009, 28:445-454. 10.1016/j.clnu.2009.04.011, 19477052.
10. Adler G, Seufferlein T, Bischoff S, Brambs H-J, Feuerbach S, Grabenbauer G, Hahn S, heinemann V, Hohenberger W, Langrehr J. S3-Leitlinie "Exokrines Pankreaskarzinom" 2007. Z Gastroenterol 2007, 45:487-523. 10.1055/s-2007-963224, 17607616.
11. Pelzer U, Kubica K, Stieler J, Schwaner G, Heil M, Görner M, Mölle M, Hilbig A, Dörken B, Riess H. A randomized trial in patients with gemcitabine refractory pancreatic cancer. Final results of the CONKO 003 study. 2008, ASCO: 2008 Chicago: JCO.
12. Mitry E, Ducreux M, Ould-Kaci M, Boige V, Seitz JF, Bugat R, Breau JL, Bouche O, Etienne PL, Tigaud JM. Oxaliplatin combined with 5-FU in second line treatment of advanced pancreatic adenocarcinoma. Results of a phase II trial. Gastroenterol Clin Biol 2006, 30:357-363.
13. Ulrich-Pur H, Raderer M, Verena Kornek G, Schull B, Schmid K, Haider K, Kwasny W, Depisch D, Schneeweiss B, Lang F. Irinotecan plus raltitrexed vs raltitrexed alone in patients with gemcitabine-pretreated advanced pancreatic adenocarcinoma. Br J Cancer 2003, 88:1180-1184. 2747555, 12698181, 10.1038/sj.bjc.6600883.
14. Schoenfeld D. The asymptomatic properties of nonparametric tests for comparing survival distributions. Biometrika 1981, 68:316-319.